Trade Soligenix, Inc. - SNGX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.118 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.001 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.091 |
| Open | 2.071 |
| 1-Year Change | 429.67% |
| Day's Range | 2.041 - 2.141 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 25, 2025 | 2.091 | -0.060 | -2.79% | 2.151 | 2.151 | 2.041 |
| Apr 24, 2025 | 2.091 | 0.110 | 5.55% | 1.981 | 2.171 | 1.981 |
| Apr 23, 2025 | 2.001 | 0.020 | 1.01% | 1.981 | 2.051 | 1.941 |
| Apr 22, 2025 | 2.011 | 0.020 | 1.00% | 1.991 | 2.051 | 1.991 |
| Apr 21, 2025 | 1.991 | 0.030 | 1.53% | 1.961 | 2.041 | 1.921 |
| Apr 17, 2025 | 2.031 | 0.040 | 2.01% | 1.991 | 2.071 | 1.981 |
| Apr 16, 2025 | 1.991 | 0.060 | 3.11% | 1.931 | 2.091 | 1.921 |
| Apr 15, 2025 | 1.971 | 0.140 | 7.65% | 1.831 | 2.001 | 1.831 |
| Apr 14, 2025 | 1.921 | 0.020 | 1.05% | 1.901 | 2.111 | 1.821 |
| Apr 11, 2025 | 2.091 | 0.180 | 9.42% | 1.911 | 2.201 | 1.901 |
| Apr 10, 2025 | 1.831 | -0.040 | -2.14% | 1.871 | 1.891 | 1.811 |
| Apr 9, 2025 | 1.911 | 0.190 | 11.04% | 1.721 | 1.941 | 1.721 |
| Apr 8, 2025 | 1.751 | -0.120 | -6.41% | 1.871 | 1.901 | 1.741 |
| Apr 7, 2025 | 1.821 | 0.150 | 8.98% | 1.671 | 1.841 | 1.671 |
| Apr 4, 2025 | 1.851 | -0.190 | -9.31% | 2.041 | 2.051 | 1.801 |
| Apr 3, 2025 | 2.086 | -0.005 | -0.24% | 2.091 | 2.101 | 2.011 |
| Apr 2, 2025 | 2.181 | 0.080 | 3.81% | 2.101 | 2.191 | 2.101 |
| Apr 1, 2025 | 2.131 | 0.010 | 0.47% | 2.121 | 2.191 | 2.121 |
| Mar 31, 2025 | 2.121 | 0.000 | 0.00% | 2.121 | 2.161 | 2.091 |
| Mar 28, 2025 | 2.141 | -0.060 | -2.73% | 2.201 | 2.241 | 2.021 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Soligenix, Inc. Company profile
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301, a novel photodynamic therapy, which has completed Phase 3 clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase 3 clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate, which is in Phase 1/2 clinical trial for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn''s disease and acute radiation enteritis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a and 1b clinical trials; SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; and ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.| Industry: | Bio Therapeutic Drugs |
Suite C-10
29 Emmons Drive
PRINCETON
NEW JERSEY 08540
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com